OBJECTIVE: To describe the epidemiology, diagnosis, risk factors, patient i
mpact, and treatment strategies for recurrent Clostridium difficile-associa
ted disease (CDAD).
DESIGN: Data were collected as part of a blinded, placebo-controlled clinic
al trial testing a new combination treatment for recurrent: CDAD. Retrospec
tive data regarding prior CDAD episodes were collected from interviews and
medical-chart review. Prospective data on the current CDAD episode, risk fa
ctors, and recurrence rates were collected during a 2-month follow-up.
SETTINGS: National referral study.
PARTICIPANTS: Patients with recurrent CDAD.
INTERVENTIONS: Treatment with a 10-day course of low-dose (500 mg/d or high
-dose (2 g/d) vancomycin or metronidazole (1 g/d).
RESULTS: Recurrent CDAD was found to have a lengthy course involving multip
le episodes of diarrhea, abdominal cramping, nausea, and fever. CDAD may re
cur over several years despite frequent treatment with antibiotics. Recurre
nce rates were similar regardless of the choice or dose of antibiotic. Recu
rrent CDAD is not a trivial disease: patients may have multiple episodes la
s many as 14), may require hospitalization, and the mean lifetime cost of d
irect medical care was $10,970 per patient Fortunately, the disease does no
t become progressively more severe as the number of episodes increase. Two
risk factors predictive for recurrent CDAD were found: increasing age and a
decreased quality-of-life score at enrollment
CONCLUSIONS: Recurrent CDAD is a persistent disease that may result in prol
onged hospital stays, additional medical costs, and rare serious complicati
ons.